- About Us
- Nano-Social Network
- Nano Consulting
- My Account
CombiMatrix Corporation (Nasdaq:CBMX) announced that today's publication in the American Journal of Human Genetics by Dr. Steve Scherer and colleagues further implicate genomic copy number variation (CNV) in the etiology of Autism Spectrum Disorder (ASD) elevating the importance of the CBMX ATScan(tm) 1.0 microarray test. The study reports the discovery of a chromosome 16p11.2 region in one percent of ASD patients identical to that described last week in the New England Journal of Medicine (Daly et al., NEJM), as well as numerous additional previously unreported ASD-risk genes. CBMX is proud to announce that, as a function of its unparalleled ability to rapidly enhance and clinically validate its genomic arrays, these new loci exist or are being added to the ATScan(tm) 1.0 establishing the CBMX platform as the most up-to-date and comprehensive diagnostic test of its kind for ASD. Moreover, as a function of CBMX's commitment to responsible and affordable diagnostics testing, the enhanced ATScan(tm) remains priced as the most affordable comparable test in the industry. We encourage physicians and patients to contact us at 949-753-0624 for more information.
In the American Journal of Human Genetics publication, researchers at the Hospital for Sick Children (SickKids) in Toronto discovered several new genomic variations, increasing the number of identified CNV regions associated to ASD. Dr. Steve Scherer, senior scientist in Genetics & Genomic Biology at SickKids and professor of Molecular Genetics at the University of Toronto noted that, "Our finding of CNVs in seven percent of autistic children not seen in their parents or controls has important clinical implications. Our data indicates that the application of microarrays can have great utility in clinical assessment of undetected syndromes underlying ASD, making it crucial to rapidly translate our basic research discoveries into validated clinical tests available to families," he said.
Dr. Mansoor Mohammed, President and CEO of CombiMatrix Molecular Diagnostics noted that, "We have dedicated considerable effort in mining the literature and leveraging our partnerships to move significant evidence-based research into quality-assured clinical diagnostics. These recent discoveries validate our business plan to establish ourselves as the preeminent provider of genome-based diagnostics. Not only am I proud to see the fruition of our efforts in the rapid development and deployment of our ATScan(tm) test, but also of the exciting pipeline of products we are currently developing and our commitment to their clinical relevance and affordability."
The following are links to the American Journal of Human Genetics article referenced above, as well as the press release from the Hospital for Sick Children (SickKids):
http://www.ajhg.org/AJHG/latestarticles ; http://www.sickkids.ca/mediaroom/custom/structuralchanges08.asp .
About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology company that develops and sells proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security, as well as other potential markets where our products and services could be utilized. The technologies we have developed include methods to produce DNA arrays for use in identifying and determining the roles of genes, gene mutations and proteins. These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
Additional information about CombiMatrix Corporation is available at www.combimatrix.com or call toll free: 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form S-1, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Fax (425) 493-2010
Copyright © PrimeNewswire, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanotubes that build themselves April 14th, 2017